What is the difference between Erelzi and Enbrel?
Medically reviewed by Drugs.com. Last updated on Sep 16, 2019.
Erelzi is the first approved biosimilar for etanercept approved in August 2016, and the third biosimilar available on the US market.
A biosimilar is a biological product that is “highly similar” to a U.S.-licensed reference biological (in this case Enbrel). The FDA has determined there are no clinically meaningful differences between the biological product Erelzi and the original reference product Enbrel in terms of safety, purity, and potency. However, a biosimilar is not considered a “generic” in the same way that a traditional drug is determined to be a generic.
Erelzi is used for the same five indications found on Enbrel product labeling: - rheumatoid arthritis, - polyarticular juvenile idiopathic arthritis, - psoriatic arthritis, - ankylosing spondylitis, and - plaque psoriasis.
It’s important to note that Erelzi is not an interchangeable product with Enbrel at the pharmacy level. Physicians must write the prescription specifically for Erelzi, as pharmacists cannot automatically substitute Erelzi for Enbrel.
For more information, see Comparing Enbrel vs Erelzi
Related Medical Questions
- What are the new drugs for the treatment of rheumatoid arthritis (RA)?
- Can Enbrel be taken with antibiotics?
- What are the new drugs for the treatment of plaque psoriasis?
- How many biosimilars have been approved in the United States?
- How long does it take for Enbrel to work?
- How long can Enbrel be left unrefrigerated?
- Do Enbrel injections hurt?
Related Support Groups
- Enbrel (20 questions, 200 members)
- Rheumatoid Arthritis (231 questions, 1222 members)
- Psoriatic Arthritis (29 questions, 240 members)
- Juvenile Idiopathic Arthritis
- Plaque Psoriasis (30 questions, 63 members)
- Juvenile Rheumatoid Arthritis
- Ankylosing Spondylitis (18 questions, 195 members)